Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 ± pertuzumab in HER2-positive advanced breast cancer with brain metastases after pyrotinib
ChiCTR2500108436Phase 4Not yet recruiting
- Sponsor
- Changde First People's Hospital
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of trastuzumab rezetecan in breast cancer and brain metastases (2 arms), sponsored by Changde First People's Hospital. Primary endpoint: Intracranial objective response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2500108436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108436.